Update on the MDS-Sponsored Systematic Review On Clinical Rating Scales for Huntington’s Disease: motor, cognitive, functional ability and quality of life domains
Objective: To provide an update on the MDS-sponsored Systematic Review of Rating Scales for Huntington’s Disease (HD). Background: The use and validity of clinical rating…Longitudinal Study of Cortico-Striatal Functional Connectivity in Huntington’s Disease Measured with High-Field Functional MRI.
Objective: To assessed functional connectivity by using functional Magnetic Resonance Imaging (fMRI) at 7 Tesla as baseline and one year thereafter. Background: Our previous study…Gait Analysis in Patients with Huntington’s Disease
Objective: The aim of this study is to investigate the temporospatial gait parameters in patients with HD in comparison with healthy control. Background: Gait disturbance…Hung up knee jerk reflex in Huntington’s disease: A clinical and neurophysiological study
Objective: Evaluate the presence of Hung-up Knee jerk reflex (HUKJR) in premanifest and symptomatic Huntington’s Disease (HD) patients and its neurophysiological correlate. Background: The HUKJR is a…Dopamine transporter scan finding in patients with chorea.
Objective: To evaluate dopamine transporter scan findings in patients with chorea. Background: Chorea is nonrepetitive irregular involuntary movement with distal predominance. They are caused by…Imaging of phosphodiesterase 10 A (PDE10A) enzyme levels in the living human brain of Huntington’s disease gene expansion carriers and healthy controls with positron emission tomography.
Objective: The objective of this study was to examine the loss of Phosphodiesterase 10A enzyme (PDE10A) across a broad spectrum of Huntington’s disease (HD) stages.…Inhibiting sphingosine-1-phosphate lyase as a possible therapy in Huntington’s disease
Objective: To advance our understanding of the process by which the mutant huntingtin (mHTT) protein contributes to neurodegeneration and translate that knowledge to potentially effective disease…Effect of Pridopidine on Total Functional Capacity (TFC) in Huntington Disease (HD): Results of a Cohort Comparison of Open-HART and Historical Placebo Subjects
Objective: To measure functional decline by TFC change in HD patients treated with open-label pridopidine at 45 mg BID (Open-HART) for 36 months (mos), and…Implementation and Validation of a Biometric Solution for Remote Monitoring of Motor Symptoms in Patients with Huntington Disease in a Phase II Clinical Trial
Objective: To implement and validate quantification of motor dysfunction in a Huntington disease (HD) clinical trial using machine learning algorithmic analysis derived from biometric monitoring…A Descriptive Analysis of a Real-World Population With Huntington Disease-Associated Chorea (HDAC) Treated With Tetrabenazine: Findings From an Electronic Medical Records (EMR) Database
Objective: To examine clinical and treatment information about HDAC in patients (pts) prescribed tetrabenazine (TBZ). Background: Huntington disease is a hereditary movement disorder, with chorea…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.